These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6598578)

  • 1. Treatment of staphylococcal pyelonephritis in rats with N-formimidoyl thienamycin.
    Guze PA; Kalmanson GM; Ishida K; Freedman LR; Guze LB
    Chemioterapia; 1984 Feb; 3(1):53-6. PubMed ID: 6598578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [N-Formimidoyl-thienamycin in Animal Studies].
    Ritzerfeld W
    Arzneimittelforschung; 1983; 33(3):470-2. PubMed ID: 6575782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.
    Norrby SR; Alestig K; Björnegård B; Burman LA; Ferber F; Huber JL; Jones KH; Kahan FM; Kahan JS; Kropp H; Meisinger MA; Sundelof JG
    Antimicrob Agents Chemother; 1983 Feb; 23(2):300-7. PubMed ID: 6573157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thienamycin: development of imipenen-cilastatin.
    Kahan FM; Kropp H; Sundelof JG; Birnbaum J
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():1-35. PubMed ID: 6365872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.
    Birnbaum J; Kahan FM; Kropp H; MacDonald JS
    Am J Med; 1985 Jun; 78(6A):3-21. PubMed ID: 3859213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study comparing clinical efficacy and safety of thienamycin formamidine (MK0787)/renal dipeptidase inhibitor (MK0791) and cefazolin.
    Ribner BS; Raeder R; Hollstein M; Freimer EH
    J Antimicrob Chemother; 1983 Oct; 12(4):387-91. PubMed ID: 6358177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal penetration of N-formimidoyl thienamycin in normal rabbits: potentiation by coadministration of renal dipeptidase enzyme inhibitor.
    Chow AW; Finlay KR; Stiver HG; Carlson CL
    Antimicrob Agents Chemother; 1983 Apr; 23(4):634-6. PubMed ID: 6574725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics of imipenem-cilastatin in neonates.
    Gruber WC; Rench MA; Garcia-Prats JA; Edwards MS; Baker CJ
    Antimicrob Agents Chemother; 1985 Apr; 27(4):511-4. PubMed ID: 3859243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
    Calandra GB; Hesney M; Brown KR
    Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular penetration of N-formimidoyl thienamycin (MK-787) and potentiation by dipeptidase inhibitor (MK-791).
    Finlay KR; Carlson CL; Chow AW
    Invest Ophthalmol Vis Sci; 1983 Aug; 24(8):1147-9. PubMed ID: 6575970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro activity of N-formimidoyl thienamycin compared with other broad-spectrum cephalosporins and with clindamycin and metronidazole.
    Tischhauser G; Kayser FH
    Infection; 1983; 11(4):219-26. PubMed ID: 6578202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections.
    Fan W; del Busto R; Love M; Markowitz N; Cendrowski C; Cardenas J; Quinn E; Saravolatz L
    Antimicrob Agents Chemother; 1986 Jan; 29(1):26-9. PubMed ID: 3460521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of N-formimidoyl thienamycin and influence of a renal dipeptidase inhibitor in experimental meningitis.
    Washburn DE; Perfect JR; Durack DT
    J Antimicrob Chemother; 1983 Jul; 12(1):39-45. PubMed ID: 6578210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyonephrosis presenting as toxic shock syndrome in infancy.
    Alpert G; Campos JM; Snyder HM
    Pediatr Infect Dis; 1985; 4(5):561-2. PubMed ID: 4047968
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin.
    Witte JL; Sapico FL; Canawati HN
    Antimicrob Agents Chemother; 1982 Nov; 22(5):906-8. PubMed ID: 6960806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
    Verpooten GA; Verbist L; Buntinx AP; Entwistle LA; Jones KH; De Broe ME
    Br J Clin Pharmacol; 1984 Aug; 18(2):183-93. PubMed ID: 6593092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.
    Dajcs JJ; Hume EB; Moreau JM; Caballero AR; Cannon BM; O'Callaghan RJ
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1432-7. PubMed ID: 10798659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cefazolin microspheres to treat localized methicillin-resistant Staphylococcus aureus infections in rats.
    Fallon MT; Shafer W; Jacob E
    J Surg Res; 1999 Sep; 86(1):97-102. PubMed ID: 10452874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of cilastatin sodium, an inhibitor of dehydropeptidase-I, on human urinary peptide excretion. Patients with renal insufficiency].
    Kumon H; Nasu Y; Ohmori H; Kodama H; Konishi Y
    Jpn J Antibiot; 1987 Sep; 40(9):1571-83. PubMed ID: 3480361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.
    Norrby SR; Alestig K; Ferber F; Huber JL; Jones KH; Kahan FM; Meisinger MA; Rogers JD
    Antimicrob Agents Chemother; 1983 Feb; 23(2):293-9. PubMed ID: 6573156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.